• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Perspectives in the assessment and management of patients with primary hyperoxaluria type I.

作者信息

Morgan S H, Watts R W

机构信息

Division of Inherited Metabolic Diseases, MRC Clinical Research Centre, Harrow, Middlesex, England.

出版信息

Adv Nephrol Necker Hosp. 1989;18:95-106.

PMID:2493726
Abstract

In normal adults the urinary excretion of oxalate rarely exceeds 0.5 mmol/24 hours-1 despite dietary and seasonal fluctuations of intake and absorption. Hyperoxaluria may be encountered in a number of disease states because of increased absorption of dietary oxalate or derangements of metabolism (Table 1). More unusually, hyperoxaluria may arise from one of three inborn errors of metabolism, i.e., the primary hyperoxalurias. The most common, primary hyperoxaluria type I (PHI), is recessively inherited; it will be discussed in detail in this paper. Primary hyperoxaluria type II, caused by a deficiency of D-glycerate dehydrogenase (EC 1.1.1.29), has a similar clinical pattern of disease, but has been described in only a very few families. More recently, another idiopathic form of hyperoxaluria has been defined (type III). It is likely that this form results from a primary defect in oxalate absorption in the absence of any morphologically or functionally definable intestinal disease; a satisfactory response to dietary restriction of oxalate, along with the use of thiazide diuretics, has been described.

摘要

相似文献

1
Perspectives in the assessment and management of patients with primary hyperoxaluria type I.
Adv Nephrol Necker Hosp. 1989;18:95-106.
2
[Primary hyperoxaluria].[原发性高草酸尿症]
Nephrologie. 1995;16(6):399-406.
3
[Primary hyperoxaluria].[原发性高草酸尿症]
Nephrol Ther. 2011 Jul;7(4):249-59. doi: 10.1016/j.nephro.2011.03.004. Epub 2011 Jun 2.
4
The primary hyperoxalurias.原发性高草酸尿症
Semin Nephrol. 2008 Mar;28(2):152-62. doi: 10.1016/j.semnephrol.2008.01.008.
5
[Primary hyperoxaluria].[原发性高草酸尿症]
Rev Med Brux. 1996 Apr;17(2):67-74.
6
[Massive hyperoxaluria].
Rev Med Suisse Romande. 2004 Aug;124(8):477-82.
7
Primary hyperoxaluria type 1: strategy for organ transplantation.1 型原发性高草酸尿症:器官移植策略。
Curr Opin Organ Transplant. 2010 Oct;15(5):590-3. doi: 10.1097/MOT.0b013e32833e35f5.
8
[Pyridoxine can normalize oxaluria in idiopathic renal lithiasis].[吡哆醇可使特发性肾石病患者的草酸盐尿恢复正常]
Schweiz Med Wochenschr. 1986 Dec 13;116(50):1783-6.
9
[Primary hyperoxaluria].[原发性高草酸尿症]
Ugeskr Laeger. 1989 Jul 17;151(29):1856-9.
10
Hyperoxaluria and systemic oxalosis: current therapy and future directions.高草酸尿症与全身性草酸中毒:当前治疗方法与未来方向
Expert Opin Pharmacother. 2006 Oct;7(14):1887-96. doi: 10.1517/14656566.7.14.1887.

引用本文的文献

1
Initial manifestation of primary hyperoxaluria type I in adults-- recognition, diagnosis, and management.成人原发性I型高草酸尿症的初始表现——识别、诊断与管理
West J Med. 1996 Jan;164(1):42-53.
2
[Type I oxalosis in childhood--studies within the scope of terminal renal failure in the child].[儿童I型草酸盐中毒——儿童终末期肾衰竭范围内的研究]
Klin Wochenschr. 1989 Nov 17;67(22):1156-67. doi: 10.1007/BF01726118.
3
Excessive urinary oxalate excretion after combined renal and hepatic transplantation for correction of hyperoxaluria type 1.
Eur J Pediatr. 1990 Nov;150(1):56-8. doi: 10.1007/BF01959482.
4
Combined liver-kidney transplantation in a child with primary hyperoxaluria.一名原发性高草酸尿症患儿的肝肾联合移植
Pediatr Nephrol. 1991 May;5(3):332-4. doi: 10.1007/BF00867495.
5
Treatment of inherited metabolic disorders by liver transplantation.通过肝移植治疗遗传性代谢紊乱
J Inherit Metab Dis. 1991;14(4):604-18. doi: 10.1007/BF01797930.
6
Orthotopic liver transplantation in liver-based metabolic disorders.基于肝脏的代谢紊乱中的原位肝移植
Eur J Pediatr. 1992;151 Suppl 1:S32-8. doi: 10.1007/BF02125800.